U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06826313) titled 'A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors' on Feb. 10.
Brief Summary: A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
BIOLOGICAL: VRT106
Intravenous drip administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....